Open AccessHow Often Does Modern Neoadjuvant Chemotherapy Downstage Patients to Breast-Conserving Surgery?
Author(s) -
Oriana Petruolo,
Varadan Sevilimedu,
Giacomo Montagna,
Tiana Le,
Monica Morrow,
Andrea V. Barrio
Publication year - 2020
Publication title -
annals of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.764
H-Index - 173
eISSN - 1534-4681
pISSN - 1068-9265
DOI - 10.1245/s10434-020-08593-5
Subject(s) - medicine , breast cancer , surgical oncology , oncology , odds ratio , univariate analysis , exact test , neoadjuvant therapy , breast conserving surgery , breast surgery , mastectomy , cancer , multivariate analysis
Neoadjuvant chemotherapy (NAC) has been proven to increase breast-conserving surgery (BCS) rates, but data are limited on conversion rates from BCS-ineligible (BCSi) to BCS-eligible (BCSe), specifically, in patients with large tumors.